

Efficacy of anakinra in active ankylosing spondylitis: a controlled imaging study

Annals of the Rheumatic Diseases

63, 1041-1045

DOI: [10.1136/ard.2004.020800](https://doi.org/10.1136/ard.2004.020800)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Biological therapies in the spondyloarthritides—the current state. <i>British Journal of Rheumatology</i> , 2004, 43, 1072-1084.	2.5	89
3	Major advances in ankylosing spondylitis: more to come. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 383-387.	0.5	1
4	Management and treatment of ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 418-425.	2.0	16
6	Interleukin-1: a new therapeutic target for ankylosing spondylitis?. <i>Joint Bone Spine</i> , 2005, 72, 357-358.	0.8	12
7	On-Column Refolding and Purification of Recombinant Human Interleukin-1 Receptor Antagonist (rHuIL-1ra) Expressed as Inclusion Body in <i>Escherichia coli</i> . <i>Biotechnology Letters</i> , 2005, 27, 1177-1182.	1.1	7
8	Novel therapies for ankylosing spondylitis. <i>Current Rheumatology Reports</i> , 2005, 7, 182-187.	2.1	1
9	Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 296-298.	0.5	205
10	Updated consensus statement on biological agents, specifically tumour necrosis factor \hat{A} (TNF \hat{A}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, iv2-iv14.	0.5	156
11	Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 839-844.	0.5	98
13	Anakinra in the treatment of rheumatic disease. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 331-340.	1.3	14
14	Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 869-883.	0.9	3
15	A comparative evaluation of MRI, radionuclide bone scan and plain radiographs in Indian patients with spondyloarthropathy. <i>Indian Journal of Rheumatology</i> , 2006, 1, 53-59.	0.2	3
17	The Role of IL-1 and IL-1Ra in Joint Inflammation and Cartilage Degradation. <i>Vitamins and Hormones</i> , 2006, 74, 371-403.	0.7	161
18	Inhibition of IL-1, IL-6, and TNF- \hat{A} in immune-mediated inflammatory diseases. <i>Seminars in Immunopathology</i> , 2006, 27, 391-408.	4.0	127
19	Non-major-histocompatibility-complex genetics of ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 611-621.	1.4	37
20	Ankylosing spondylitis: New treatment modalities. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 559-570.	1.4	11
21	Assessments in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 521-537.	1.4	61
22	Is IL-1 a good therapeutic target in the treatment of arthritis?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 879-896.	1.4	144

#	ARTICLE	IF	CITATIONS
23	Spondyloarthropathy: disease at the crossroads of immunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 949-967.	1.4	15
24	Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: An analysis of three Canadian populations. <i>Arthritis and Rheumatism</i> , 2006, 54, 974-985.	6.7	69
25	Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 211-218.	3.2	20
26	MRI of the Sacroiliac Joints in Patients with Moderate to Severe Ankylosing Spondylitis. <i>American Journal of Roentgenology</i> , 2006, 187, 1420-1426.	1.0	100
27	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, iii2-iii15.	0.5	57
28	Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 423-432.	0.5	188
29	Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1305-1309.	0.5	103
30	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, iii2-iii22.	0.5	104
31	Sustained response to anakinra in ankylosing spondylitis. <i>Rheumatology</i> , 2007, 47, 223-224.	0.9	30
32	Ankylosing spondylitis. <i>Lancet</i> , The, 2007, 369, 1379-1390.	6.3	1,558
33	Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 7.	1.0	37
35	What is the role for interleukin-1 receptor antagonist in rheumatic disease?. <i>Joint Bone Spine</i> , 2007, 74, 223-226.	0.8	16
36	Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population. <i>Rheumatology International</i> , 2007, 27, 605-611.	1.5	30
38	Physiopathologie de la spondylarthrite ankylosante. <i>Actualités. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT 0/Overlo</i>	0.0	0
39	Pathophysiology of ankylosing spondylitis: What's new?. <i>Joint Bone Spine</i> , 2008, 75, 656-660.	0.8	28
40	Nonsurgical management of ankylosing spondylitis. <i>Neurosurgical Focus</i> , 2008, 24, E5.	1.0	5
41	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, iii2-iii25.	0.5	99
42	Predicting outcome in ankylosing spondylitis. <i>Rheumatology</i> , 2008, 47, 942-945.	0.9	20

#	ARTICLE	IF	CITATIONS
43	The pathogenesis of ankylosing spondylitis. <i>Neurosurgical Focus</i> , 2008, 24, E3.	1.0	25
44	At the horizon of innovative therapy in rheumatology: new biologic agents. <i>Current Opinion in Rheumatology</i> , 2008, 20, 269-275.	2.0	32
45	The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2009, 28, 397-402.	1.0	68
46	Assessment and treatment of psoriatic spondylitis. <i>Current Rheumatology Reports</i> , 2009, 11, 278-283.	2.1	5
47	A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. <i>Rheumatology International</i> , 2009, 29, 1123-1135.	1.5	31
48	Ankylosing spondylitis: recent developments and anaesthetic implications. <i>Anaesthesia</i> , 2009, 64, 540-548.	1.8	75
50	Role of whole-body magnetic resonance imaging in diagnosing early spondyloarthritis. <i>European Journal of Radiology</i> , 2009, 71, 182-188.	1.2	43
51	Therapy of Spondyloarthritides. <i>Advances in Experimental Medicine and Biology</i> , 2009, 649, 133-147.	0.8	12
52	Update on Biologic Therapy in the Management of Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 325-331.	2.1	24
53	Anti-IL-1 molecules: New comers and new indications. <i>Joint Bone Spine</i> , 2010, 77, 102-107.	0.8	84
54	Les anti-IL-1: nouvelles molécules et nouvelles indications. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 124-130.	0.0	0
55	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, i2-i29.	0.5	113
56	Spondyloarthritides: evolving therapies. <i>Arthritis Research and Therapy</i> , 2010, 12, 221.	1.6	13
57	Current therapeutics for spondyloarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2469-2477.	0.9	7
58	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, i2-i36.	0.5	287
60	Cell-specific effects of TNF- α and IL-1 β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. <i>Laboratory Investigation</i> , 2011, 91, 1434-1442.	1.7	72
61	Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition. <i>Current Opinion in Rheumatology</i> , 2012, 24, 252-260.	2.0	30
62	Management and evaluation of extra-articular manifestations in spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 413-422.	1.2	49

#	ARTICLE	IF	CITATIONS
63	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i2-i45.	0.5	71
64	Comorbidities in Patients with Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 523-538.	0.8	33
65	Enthesopathy in patients with familial Mediterranean fever: increased prevalence in M694 V variant. <i>Rheumatology International</i> , 2013, 33, 1933-1937.	1.5	24
66	Treating inflammation by blocking interleukin-1 in humans. <i>Seminars in Immunology</i> , 2013, 25, 469-484.	2.7	471
67	Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 71-86.	1.0	10
68	Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 5-7.	1.0	5
69	Therapeutics for the treatment of spondyloarthritis: what, when and whom. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 73-88.	0.3	0
70	Documentation of off-label use of biologics in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii35-ii51.	0.5	7
71	Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes. <i>Open Access Rheumatology: Research and Reviews</i> , 2014, 6, 15.	0.8	13
72	An Expanding Role for Interleukin-1 Blockade from Gout to Cancer. <i>Molecular Medicine</i> , 2014, 20, S43-S58.	1.9	87
73	Inflammatory pathways in spondyloarthritis. <i>Molecular Immunology</i> , 2014, 57, 28-37.	1.0	113
74	Genetics of ankylosing spondylitis. <i>Molecular Immunology</i> , 2014, 57, 2-11.	1.0	109
75	Spondyloarthritis: from unifying concepts to improved treatment. <i>Rheumatology</i> , 2014, 53, 1547-1559.	0.9	33
76	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , 2015, 42, 665-681.	1.0	42
77	Emerging drugs for the treatment of axial and peripheral spondyloarthritis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 1-14.	1.0	40
78	Pharmacological therapy of spondyloarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1495-1504.	0.9	12
79	IL-17 Inhibition in Axial Spondyloarthritis. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 221-230.	0.6	2
80	Biologics in spondyloarthritis: TNF α inhibitors and other agents. <i>Immunotherapy</i> , 2015, 7, 669-681.	1.0	14

#	ARTICLE	IF	CITATIONS
81	Autoinflammation and HLA-B27: Beyond Antigen Presentation. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 460-469.	1.0	14
82	New treatment targets for axial spondyloarthritis: Table 1. <i>Rheumatology</i> , 2016, 55, ii38-ii42.	0.9	21
83	The synovio-enthesal complex in enthesoarthritis. <i>Clinical and Experimental Medicine</i> , 2016, 16, 109-124.	1.9	7
84	Evaluating the autoinduction expression system and one-step purification for high-level expression and purification of gallbladder-derived rhIL-1 α . <i>Biotechnology and Applied Biochemistry</i> , 2017, 64, 20-26.	1.4	2
85	Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies. <i>Current Rheumatology Reports</i> , 2017, 19, 8.	2.1	8
86	Patient Burden of Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 383-391.	0.5	85
87	Endothelial cells: From innocent bystanders to active participants in immune responses. <i>Autoimmunity Reviews</i> , 2017, 16, 951-962.	2.5	109
88	Les enthésites. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, A21-A28.	0.0	0
89	Biologic Therapy for HLA-B27-associated Ocular Disorders. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 169-178.	1.0	17
90	New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications. <i>Modern Rheumatology</i> , 2017, 27, 198-209.	0.9	47
91	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 77-87.	1.1	40
92	Biologics for treating axial spondyloarthritis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 641-652.	1.4	20
93	Interleukin 1 gene polymorphism and susceptibility to disease. <i>Immunological Reviews</i> , 2018, 281, 40-56.	2.8	59
94	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. <i>Human Molecular Genetics</i> , 2018, 27, 875-890.	1.4	58
95	Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 269-281.	2.9	16
96	Beyond the TNF- α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. <i>Drugs</i> , 2018, 78, 1397-1418.	4.9	16
97	Personalized Axial Spondyloarthritis Care. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 158-173.	0.6	1
98	NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis. <i>Clinica Chimica Acta</i> , 2018, 486, 269-274.	0.5	28

#	ARTICLE	IF	CITATIONS
99	Role of inflammasomes in inflammatory autoimmune rheumatic diseases. Korean Journal of Physiology and Pharmacology, 2018, 22, 1.	0.6	81
100	Factors Associated With Initiation of Biologics in Patients With Axial Spondyloarthritis in an Urban Asian City. Journal of Clinical Rheumatology, 2019, 25, 59-64.	0.5	7
101	Utility of Magnetic Resonance Imaging in Diagnosis and Monitoring Enthesitis in Patients with Spondyloarthritis: An OMERACT Systematic Literature Review. Journal of Rheumatology, 2019, 46, 1207-1214.	1.0	10
102	Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 135.	1.6	27
103	Biologic Treatment of Axial Spondyloarthritis. , 2019, , 227-242.		2
104	Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis. PLoS Genetics, 2019, 15, e1008038.	1.5	41
105	FMF Is Associated With a Wide Spectrum of MHC Class I- and Allied SpA Disorders but Not With Classical MHC Class II-Associated Autoimmune Disease: Insights From a Large Cohort Study. Frontiers in Immunology, 2019, 10, 2733.	2.2	19
106	Magnetic Resonance Imaging of Enthesitis in Spondyloarthritis, Including Psoriatic Arthritisâ€™Status and Recent Advances. Frontiers in Medicine, 2020, 7, 296.	1.2	18
107	From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. Frontiers in Immunology, 2021, 12, 624632.	2.2	16
108	IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?. Frontiers in Immunology, 2020, 11, 623874.	2.2	16
109	Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis. Arthritis and Rheumatology, 2021, 73, 1189-1199.	2.9	32
110	Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. Nature Reviews Rheumatology, 2021, 17, 387-404.	3.5	130
111	Axial spondyloarthritis: emerging drug targets. Expert Opinion on Therapeutic Targets, 2021, 25, 1-12.	1.5	3
112	Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?. Seminars in Arthritis and Rheumatism, 2021, 51, 1147-1161.	1.6	6
113	Off-label use of anti-IL-1 drugs in rheumatic diseases. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110065.	1.0	15
115	Bone Loss in the Spondyloarthropathies: Role of Osteoclast, RANKL, RANK and OPG in the Spondyloarthropathies. Advances in Experimental Medicine and Biology, 2009, 649, 85-99.	0.8	15
116	Imaging Inflamed Synovial Joints. Methods in Molecular Medicine, 2007, 135, 3-26.	0.8	6
117	Pelvis, Hip and Groin. , 2007, , 235-263.		2

#	ARTICLE	IF	CITATIONS
118	Management of ankylosing spondylitis. , 2011, , 1157-1177.e3.		2
120	Recent advances in managing axial spondyloarthritis. F1000Research, 2020, 9, 697.	0.8	6
121	Biochemistry of Back Pain. Open Spine Journal, 2013, 5, 12-18.	0.4	6
122	Imaging in Ankylosing Spondylitis. , 2006, , 71-81.		2
123	Biologic Therapies in Spondyloarthritisâ€”The Current State. , 2006, , 169-185.		0
125	Quality of Life in Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy: Chinese Perspectives. , 2010, , 3955-3964.		0
128	Cytokine neutralizers. , 2015, , 479-484.		1
129	ADVANCES IN THERAPIES FOR SPONDYLOARTHROPATHIES. , 2015, , 109-128.		0
130	The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease. Autoimmunity, 2022, 55, 1-7.	1.2	22
132	Treatment of ankylosing spondylitis: focus on etanercept. Biologics: Targets and Therapy, 2007, 1, 45-51.	3.0	2
133	Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clinical and Experimental Rheumatology, 2011, 29, 322-30.	0.4	12
134	Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease. Current Osteoporosis Reports, 2022, 20, 170-185.	1.5	9
135	IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature Reviews Rheumatology, 2022, 18, 448-463.	3.5	47
136	The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor) Tj ETQq1 1 0.784314 rgBT /Overlock 1 0.2 5		
137	The effect of subchondral oedema in T2-weighted Dixon MRI sequence evaluation of sacroiliac joint erosion in axial spondyloarthropathy. Clinical Radiology, 2022, , .	0.5	0
138	The Role of Neuro-Immune Interactions in Chronic Pain: Implications for Clinical Practice. Journal of Pain Research, 0, Volume 15, 2223-2248.	0.8	8
139	Inflammasomes and their roles in arthritic disease pathogenesis. Frontiers in Molecular Biosciences, 0, 9, .	1.6	7
140	Metallothionein-1 is Positively Correlated with Inflammation and Ankylosing Spondylitis Activity. Journal of Inflammation Research, 0, Volume 15, 5935-5944.	1.6	1

#	ARTICLE	IF	CITATIONS
141	From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium” Journal of Clinical Medicine, 2023, 12, 527.	1.0	1
142	Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?. Current Rheumatology Reports, 2023, 25, 56-67.	2.1	3
143	The intricate relationship between autoimmunity disease and neutrophils death patterns: a love-hate story. Apoptosis: an International Journal on Programmed Cell Death, 2023, 28, 1259-1284.	2.2	4